Andrew Christopher Harris MD

Clinical Lecturer, Pediatrics
Pediatric Hematology/Oncology, Pediatrics

Video profile


U of M Internal Medicine Hematology/Oncology

C.S. Mott Children's Hospital
1540 E. Hospital Dr., Level 7, Reception C
Ann Arbor

U of M Pediatric Hematology Oncology

CS Mott Children's Hospital Floor 7
1540 E Hospital Dr SPC 4257
Ann Arbor


Medical School or Training

  • Case Western Reserve University School of Medicine, 2005


  • Cleveland Clinic Hospital/Credentialing, Pediatrics, OH, 2008


  • Pediatric Hematology/Oncology, University of Michigan Health System, 2011

Board Certification

  • Pediatrics


Dr. Harris is part of a research team with Drs. Levine and Ferrara. His primary research focus is the development and clinical application of blood tests (biomarkers) to help predict, diagnose and determine therapy for acute graft-versus-host disease (GVHD), the major complication of allogeneic blood & bone marrow transplantation.  He has a particular interest in the pathophysiology of lower gastrointestinal GVHD, the most worrisome site of GVHD involvement.  Recent Publications:

  1. Ferrara JLM & Harris AC, Greenson JK, Braun T, Holler E, Teshima T, Levine JE, Choi SW, Huber E, Landfried K, Vander Lugt MT, Reddy P, Ching  A, Zhang Q, Hanash S, Paczesny P. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood, 118:6702-8, 2011.
  2. Harris AC, Ferrara JLM, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Landfried K, Akashi K,  Vander Lugt MT, Couriel DR, Reddy P, Paczesny S. Plasma biomarkers of lower gastrointestinal and liver acute graft-versus-host disease. Blood, 119:2960-3, 2012.
  3. Harris AC, Ferrara JLM, Levine JE. Advances in predicting acute GVHD. Br J Haematol, 160(3):288-302, 2013.
  4. Harris AC, Kitko CL, Couriel DR, Braun TM, Choi SW, Magenau J, Mineishi S, Pawarode A, Yanik G, Levine JE. Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica, 98(2):179-84, 2013.
  5. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong CH, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Ferrara JL, Paczesny S. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med, 8;369(6):529-39, 2013.







Dr. Andrew Harris received his undergraduate degree from Bowling Green State University and his medical degree from the Case Western Reserve University School of Medicine. He completed his pediatric residency at the Cleveland Clinic Hospital and then came to the University of Michigan for his fellowship in pediatric hematology, oncology and bone marrow transplantation. He joined of the University of Michigan faculty in the Department of Pediatrics & Communicable Diseases after completing fellowship in 2011.  When not at work, Dr. Harris enjoys playing and watching sports, especially when these activities involve his three children.  He is also an avid outdoorsman who enjoys camping, backpacking and hiking.